Blog
RSS FeedPosted by Michael Wonder on 13 Dec 2017
New concentrated insulin approved and available for Canadian patients
12 December 2017 - Entuzity KwikPen is five times more concentrated than the current option. ...
Posted by Michael Wonder on 05 Dec 2017
Health Canada approves Rydapt (midostaurin), first targeted therapy for common form of acute myeloid leukaemia
5 December 2017 - Targeted therapy treats most common gene mutation (FLT3) found in more than one third of AML patients. ...
Posted by Michael Wonder on 05 Dec 2017
Health Canada approves Dupixent, the first targeted treatment for adults with moderate-to-severe atopic dermatitis
4 December 2017 - Patients saw a clinically significant improvement in the condition of their skin and reduction in itch within ...
Posted by Michael Wonder on 05 Dec 2017
EMD Serono receives Health Canada Notice of Compliance for Mavenclad (cladribine tablets) for patients living with relapsing-remitting multiple sclerosis
4 December 2017 - EMD Serono Canada announced today that Health Canada has approved Mavenclad (cladribine tablets) as monotherapy for the ...
Posted by Michael Wonder on 28 Nov 2017
Sobi receives approval from Health Canada for Orfadin oral suspension for the treatment of HT-1
27 November 2017 - Swedish Orphan Biovitrum (Sobi) has received approval from Health Canada for an oral suspension formulation of Orfadin ...
Posted by Michael Wonder on 22 Nov 2017
Health Canada approves Victoza as the first and only GLP-1 receptor agonist to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease
21 November 2017 - Cardiovascular disease is the leading cause of death for people with T2D, who are at a 2 ...
Posted by Michael Wonder on 16 Nov 2017
Janssen announces Health Canada approval of Tremfya (guselkumab) for the treatment of adult moderate to severe plaque psoriasis
15 November 2017 - Tremfya is the first approved biologic that selectively blocks interleukin-23. ...
Posted by Michael Wonder on 14 Nov 2017
Xalkori approved by Health Canada for the treatment of patients with ROS1-positive locally advanced or metastatic non-small-cell lung cancer
14 November 2017 - First Health Canada approved treatment for Canadians with ROS1 non-small-cell lung cancer. ...
Posted by Michael Wonder on 07 Nov 2017
Health Canada approves Imfinzi (durvalumab) for previously treated patients with advanced bladder cancer
6 November 2017 - Approval granted based on promising tumour response rate and duration of response. ...
Posted by Michael Wonder on 06 Nov 2017
Health Canada approves Otsuka and Lundbeck's Abilify Maintena (aripiprazole once Monthly) as treatment for bipolar I disorder in adults
2 November 2017 - Otsuka Canada and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for Abilify Maintena ...
Posted by Michael Wonder on 05 Nov 2017
Health Canada approves Actemra (tocilizumab) for Canadians living with giant cell arteritis
2 November 2017 - Actemra is the first non-steroid treatment designed to directly target the interleukin-6 (IL-6) receptor, offering a ...
Posted by Michael Wonder on 02 Nov 2017
Pediapharm receives Health Canada approval for Cuvposa
1 November 2017 - Pediapharm is very pleased to announce Health Canada's notice of compliance (approval) for Cuvposa (Glycopyrrolate oral ...
Posted by Michael Wonder on 16 Oct 2017
GSK announces first approval of Shingrix in Canada
13 October 2017 - The only shingles vaccine to achieve ≥90% efficacy in adults aged 50 and over. ...
Posted by Michael Wonder on 25 Sep 2017
Gilead receives approval in Canada for expanded indication of Epclusa (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C in patients co-infected with HIV
21 September 2017 - New data for first approved pan-genotypic once-daily single tablet regimen for chronic hepatitis C virus infection. ...
Posted by Michael Wonder on 18 Sep 2017
Amicus Therapeutics announces approval for Galafold (migalastat) for treatment of Fabry disease in Canada
14 September 2017 - First oral precision medicine for Fabry disease with broad label for Fabry patients with amenable genetic ...